Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4R7X8)

• Drug Name: 10-hydroxy-18-methoxybetaenone Drug Info
• Synonyms: CHEMBL498247; 10-hydroxy-18-methoxybetaenone; BDBM50269144

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 10644450
  TTD Drug ID: DM4R7X8

Molecule-Related Drug Atlas

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[2]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[3]
Gefitinib	DM15F0X	Solid tumour/cancer	2A00-2F9Z	Approved	[4]
Erlotinib	DMCMBHA	Non-small-cell lung cancer	2C25.Y	Approved	[5]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[6]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[7]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[8]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[9]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[7]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[10]

Drug(s) Targeting Cyclin-dependent kinase 4 (CDK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apremilast	DMTWS9E	Psoriasis vulgaris	EA90	Approved	[11]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[12]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[13]
Ribociclib succinate	DM9CIUW	Breast cancer	2C60-2C65	Approved	[14]
Trilaciclib	DMP5A4T	Small-cell lung cancer	2C25.Y	Approved	[15]
LEE011	DMMX75K	Breast cancer	2C60-2C65	Phase 3	[16]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[17]
P-276	DMMJUHD	Breast cancer	2C60-2C65	Phase 2	[18]
G1T38	DMQO2IT	Breast cancer	2C60-2C65	Phase 2	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclin-dependent kinase 4 (CDK4)	TT0PG8F	CDK4_HUMAN	Inhibitor	[1]
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[1]

References

• [1] Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases. J Nat Prod. 2000 Jun;63(6):739-45.
• [2] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [3] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [4] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [5] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [6] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [8] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [9] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [10] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [11] Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
• [12] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [16] Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
• [17] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [18] Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
• [19] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)